⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oseltamivir Carboxylate SCHEMBL28431271 | 1.00 | — | — | |
| Oseltamivir Carboxylate SCHEMBL12820854 | 1.00 | — | — | |
| Oseltamivir Carboxylate SCHEMBL4563861 | 1.00 | — | — | |
| Oseltamivir Carboxylate SCHEMBL28433596 | 1.00 | — | — | |
| Oseltamivir Carboxylate SCHEMBL17889878 | 1.00 | — | — | |
| Oseltamivir Carboxylate SCHEMBL14080012 | 1.00 | — | — | |
| Oseltamivir Carboxylate SCHEMBL182903 | 1.00 | — | — | |
| Oseltamivir Carboxylate SCHEMBL13968374 | 1.00 | — | — | |
| Oseltamivir Carboxylate SCHEMBL20607528 | 1.00 | — | — | |
| Oseltamivir Carboxylate SCHEMBL28438495 | 1.00 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2211901-B2 | VACCINATION WITH MULTIPLE CLADES OF H5 INFLUENZA A VIRUS | SEQIRUS UK LTD (GB) | 2023-04-26 | — | — | EP | disclosed |
| EP-2942062-A1 | INFLUENZA VACCINE REGIMENS FOR PANDEMIC-ASSOCIATED STRAINS | Novartis AG (CH) | 2015-11-11 | — | — | EP | disclosed |
| EP-2211901-B1 | VACCINATION WITH MULTIPLE CLADES OF H5 INFLUENZA A VIRUS | NOVARTIS AG (CH) | 2013-05-01 | — | — | EP | disclosed |
| EP-2032163-B1 | ADJUVANT-SPARING MULTI-DOSE INFLUENZA VACCINATION REGIMEN | NOVARTIS AG (CH) | 2013-01-23 | — | — | EP | disclosed |
| EP-2368572-A2 | Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture | Novartis Vaccines and Diagnostics S.r.l. (IT) | 2011-09-28 | — | — | EP | disclosed |
| EP-1951300-B1 | CHANGING TH1/TH2 BALANCE IN SPLIT INFLUENZA VACCINES WITH ADJUVANTS | NOVARTIS VACCINES & DIAGNOSTIC (IT) | 2011-06-22 | — | — | EP | disclosed |